We have previously observed that the synthetic peptide corresponding to amino acids 31-45 (PCK3145) of PSP94 can reduce prostate tumor growth in vivo. Moreover, a recently concluded phase IIa clinical trial with patients with hormone refractory prostate cancer indicated that PCK3145 down-regulates the levels of plasma matrix metalloproteinase (MMP)-9, a MMP involved in metastasis and tumor angiogenesis. The purpose of our study was to investigate the molecular mechanisms of action of PCK3145 and whether this peptide could antagonize tumor neovascularization. We show that, in a syngeneic in vivo model of rat prostate cancer, the expression of endothelial cell (EC) specific CD31, a marker of tumor vessel density, was decreased by 43% in PCK3145-treated animals. In vitro, PCK3145 specifically antagonized in a dose-dependent manner the VEGF-induced ERK phosphorylation as well as the phosphorylation of the VEGFR-2 in cultured EC (HUVEC). These anti-VEGF effects were partly reproduced by pharmacological inhibitors such as PD98059 and PTK787, suggesting that PCK3145 inhibits the tyrosine kinase activity associated to VEGFR-2, which in turn prevents intracellular signalling through the MAPK cascade. Moreover, PCK3145 was also found to inhibit the PDGF-induced phosphorylation of PDGFR in smooth muscle cells. Finally, PCK3145 inhibited in vitro EC tubulogenesis and VEGF-induced MMP-2 secretion suggesting its potential implication as an antiangiogenic agent. Our study demonstrates that PCK3145 interferes with the tyrosine kinase activity associated with VEGF signalling axis in EC. The antiangiogenic properties of this peptide could be highly beneficial and exploited in novel antiangiogenic therapies, for patients with various cancers. ' 2005 Wiley-Liss, Inc.Key words: VEGF receptor; prostate cancer; tumor angiogenesis; ERK; tyrosine kinase inhibitor Prostate secretory protein 94 (PSP94), also known as prostatic inhibin peptide or b-microseminoprotein, is one of the 3 predominant naturally occurring proteins secreted by the prostate gland along with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP).1,2 PSP94 has been shown to be differentially expressed depending upon the stage of prostate cancer progression and has been indicated as a potential prognostic marker.3 In previous studies using the PC3 xenograft mouse model and the Dunning rat R-3327 MLL model, we have shown that PSP94 can reduce prostate cancer growth in vivo, 4 and that the amino acid 31-45 region of PSP94 (PCK3145) was sufficient to elicit PSP94-mediated antitumor effects. 5 More recently, the final phase IIa clinical trial results with PCK3145 confirmed its therapeutic safety and tolerability for metastatic hormone-refractory prostate cancer (HRPC).6 This effect was in part correlated to a marked reduction in the high levels of plasma MMP-9 (values above 100 lg/ml), a gelatinase B enzyme involved in extracellular matrix (ECM) degradation and tumor invasion, of patients receiving PCK3145, suggesting a biological effect possibly related to ...